glp 1 and cholesterol Frontiers GLP-1 Cholesterol: Biomarkers & Lipid
Description
Will continue to use this medication
10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg
Systemic estradiol enters the bloodstream and circulates throughout the body
S6 Body Sculpting Treatment offers a practical solution
